Urolithiasis in a Patient With HIV Receiving Atazanavir

Atazanavir is a protease inhibitor (PI) indicated for the treatment of human immunodeficiency virus (HIV) as part of the highly active antiretroviral therapy (HAART). Limited data exist documenting the risk of patients developing urolithiasis while being treated with certain antiretroviral therapies. However, the risk of urolithiasis due to administration of atazanavir seems to exceed the combined risk associated with other drugs used for treatment of HIV. Development of a right-sided urethral calculus related to atazanavir therapy in a patient with HIV is described in this case study.